Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.
This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month
Search
Have an existing account?
Sign In
